Top CDMO Firms of 2020
Kashmore, Sindh, Pakistan, June 26 2020 (Wiredrelease) Boost SEO Metrics — London,UK (Wiredrelease) Procom Communication INC: As the globe continues to reel from the effects of the coronavirus pandemic, the question of when a vaccine will be available is at the top of everybody’s mind. While biotech and biopharmaceutical firms all around the world have been pursuing a vaccine, an unsung hero that supports these efforts are the huge contract development and manufacturing organizations (CDMO) that bear a huge brunt of the workload.
A CDMO is a company that aids pharmaceutical firms on a contractual basis, which means they handle services ranging from initial drug development through to large-scale manufacturing of treatments. In 2020, the pharmaceutical industry is leaning heavily on CDMOs to help facilitate and expedite the process of creating, testing, and developing critical treatment solutions such as a potential COVID-19 vaccine. Here are the top ten CDMO firms of 2020:
Cambrex is one of the largest CDMO firms in the world, which forged its name in developing, testing, and building small-molecule active pharmaceutical ingredients. Over time, the firm built a name as a premier CDMO firm after a series of major acquisitions that solidified the firm’s expertise. In an interesting turn of events, Cambrex was purchased by Permira Funds, a private equity firm for $2 billion in late 2019, to help optimize the company.
Recipharm is a long-standing firm in the pharmaceutical space, having recently celebrated 25 years of business. Among one of the five largest CDMO firms in the world, the company has a global presence in all corners of the world and employs over 9,000 people. Recently, Recipharm has noted a dramatic growth in interest for the company’s chloroquine antiviral drug, which has been used to aid patients with coronavirus COVID-19.
Thermo Fisher is a tremendous firm dedicated to improving human health through consumables, systems, and services. Among the firm’s notable offerings is their CDMO services. Notably, Thermo Fisher has officially entered with the development of a $475 million cell therapy collaboration center in Princeton.
Samsung Biologics is one of the largest CDMO firms in the world. In October 2018, Samsung Biologics opened up its third manufacturing plant which brings the firms’ annual production capacity to 360,000 liters a year. By 2020, Samsung Biologics estimates that it will produce 350 products across its three large-scale facilities.
Fujifilm Diosynth Biotechnologies is a world-leading biologics CDMO that is actively working to help develop a future COVID-19 therapy through one of its Denmark-based facilities. Initially founded in the Netherlands in 1923, Diosynth saw success with its extraction of insulin from bovine pancreas, which still remains one of the company’s main products.
WuXi Biologics is a Chinese headquartered CDMO firm that strongly leverages open-access, integrated technology platforms for drug development. A relatively recent firm, WuXi Biologics was founded in 2015 and went public on the Hong Kong stock exchange in 2017. While primarily based in China, the firm has expanded its global reach by building a specialized $394 million facility in Ireland.
Lonza is a Switzerland-based CDMO firm that specializes in combining technological innovation with pharmaceutical manufacturing. Founded in 1897, Lonza is among one of the oldest continuously-running pharmaceutical companies in the world and has operations spread across 24 sites around the globe today.
Catalent is a leading provider of advanced delivery technologies and development solutions for pharmaceutical solutions. Based in New Jersey, Catalent expanded its contract development and manufacturing presence through the aggressive purchases of multiple CDMOs, including Paragon Services ($1.2 billion) and Masthercell Global ($315 million).
The Center for Breakthrough Medicines is a new yet ambitious plan that seeks to become the world’s largest cell and gene therapy CDMO firm. As of early 2020, the firm sought to invest nearly $1.1 billion to redevelop a former GlaxoSmithKline site into a $500 million, 1.6 million square-foot campus in Pennsylvania. The good news for Center for Breakthrough Medicines is that development and manufacturing services oriented around gene therapy is largely untapped, which could give the firm significant future business.
Siegfried is a CDMO that offers a broad base of knowledge around complex oral and sterile creation of drugs and manufacturing. The firm has facilities based in Switzerland, Malta, Germany, and the U.S. that specialize in the manufacture and development of drug solutions.
Freddie M. Tucker
This content has been published by Boost SEO Metrics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at email@example.com.